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Abstract
Granzyme K (GrK) is a trypsin-like serine protease that is elevated in patients with sepsis and acute lung inflammation. While
GrK was originally believed to function exclusively as a pro-apoptotic protease, recent studies now suggest that GrK may
possess other non-cytotoxic functions. In the context of acute lung inflammation, we hypothesized that GrK induces pro-
inflammatory cytokine release through the activation of protease-activated receptors. The direct effect of extracellular GrK
on PAR activation, intracellular signaling and cytokine was assessed using cultured human lung fibroblasts. Extracellular GrK
induced secretion of IL-6, IL-8 and MCP-1 in a dose- and time-dependent manner in lung fibroblasts. Heat-inactivated GrK
did not induce cytokine release indicating that protease activity is required. Furthermore, GrK induced activation of both the
ERK1/2 and p38 MAP kinase signaling pathways, and significantly increased fibroblast proliferation. Inhibition of ERK1/2
abrogated the GrK-mediated cytokine release. Through the use of PAR-1 and PAR-2 neutralizing antibodies, it was
determined that PAR-1 is essential for GrK-induced IL-6, IL-8 and MCP-1 release. In summary, extracellular GrK is capable of
activating PAR-1 and inducing fibroblast cytokine secretion and proliferation.
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Introduction
Granzymes (granule-secreted enzymes) are a family of serine
proteasesthat wereonce thought to function exclusively inimmune-
mediated target cell death through a perforin-dependent mecha-
nism. In humans, there are 5 granzymes that differ in both function
and substrate specificity: Granzyme A (GrA; tryptase), Granzyme B
(GrB;aspartase),GranzymeH (GrH;chymase),GranzymeK(GrK;
tryptase) and Granzyme M (GrM; metase). Despite their initial
discovery and prediction to act as both intracellular and
extracellular proteases, traditional views have limited granzyme
function to the intracellular, perforin-dependent induction of cell
death. However, over the past few years, evidence has emerged to
challenge this view and strongly implies that granzymes exert other
non-cytotoxic roles in health and disease [1,2,3,4,5,6,7,8]
Elevated levels of GrA, GrB and GrK are observed in a wide
array of inflammatory diseases such as atherosclerosis, arthritis,
chronic obstructive pulmonary disease (COPD), idiopathic
pulmonary fibrosis (IPF), and asthma (reviewed in [4,9]). However,
while several studies have focused on the perforin-independent
functions of GrA and GrB, little is known concerning the function
of extracellular GrK [10,11,12,13,14]. GrK is found at low levels
in the plasma of healthy patients but is markedly elevated in the
plasma of patients suffering from viral infections and sepsis
[11,15]. GrK is also elevated in the bronchoalveolar lavage (BAL)
fluid of patients suffering from allergic asthma and viral
pneumonias [10,11]. Although our understanding of the proteo-
lytic regulation of extracellular GrK remains poorly understood,
recent studies have identified inter-alpha inhibitor proteins (IAIP)
as physiological inhibitors of GrK and have shown that a
reduction in plasma IAIP levels and free, unbound GrK
correspond to increased disease severity [16,17].
GrK is a highly cationic protease that displays tryptase-like
activity, which cleaves after the basic amino acids Lys or Arg and
is most closely related to GrA [18,19,20,21]. Despite sharing many
substrates with GrA, proteomic profiling has demonstrated that
GrK can target a unique set of substrates suggesting it likely
functions distinctly from that of GrA [19,22]. GrA, also a tryptase-
like protease, is capable of inducing cell detachment, cytokine
release, neurite retraction and activation of Protease-Activated
Receptor (PARs) [8,23,24,25]. PARs are a family of G-protein
coupled receptors (GCPRs) that mediate the physiological
responses to serine proteases (reviewed in [26,27]). PARs share a
unique mechanism of activation that involves the cleavage of an
N-terminal extracellular domain which leads to the unmasking of
a tethered ligand that, in turn, activates the receptor by
intramolecular binding followed by intracellular signaling
[27,28]. PAR-1 is activated by thrombin and trypsin, PAR-2 is a
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are receptors for thrombin [27,28,29].
In the present study, we investigated whether extracellular GrK
could induce PAR activation in human lung fibroblasts. GrK
induced the production of interleukin-6 (IL-6), IL-8 (CXCL8) and
monocyte chemotactic protein-1 (MCP-1)/chemokine c-c motif
ligand 2 (CCL2) in human lung fibroblasts through the activation
of PAR-1. In addition, GrK induced fibroblast proliferation in a
PAR-1-dependent manner suggesting that elevated extracellular
GrK could augment inflammation and play a role in airway
remodeling through the activation of PAR-1.
Materials and Methods
Reagents
Cell culture medium Dulbecco’s modified Eagle’s medium
(DMEM), fetal bovine serum (FBS), and PBS were obtained from
Invitrogen (Carlsbad, CA, USA). Thrombin, ERK1/2 inhibitor
U0126 and the p38 MAPK inhibitor SB202190, and the
antibiotics (penicillin and streptomycin) were obtained from Sigma
(St. Loius, MO, USA). Granzyme K was obtained from Axxora
(Burlington, ON Canada), and the PAR-1 (ATAP-2 cat no: sc-
13503) and PAR-2 (Sam11L cat no: sc-13504) neutralizing
antibodies were obtained from Santa Cruz Biotechnologies (Santa
Cruz, CA, USA). Mouse IgG (Abcam cat no 37355) was used as
an isotype control. Antibodies: Phospho-p44/42 (Cell Signaling
Technology (clone E10) cat no: 9106s), total p44/42 (Cell
Signaling Technology (clone 137F5) cat no: 4695), phospho-p38
MAPK (Cell Signaling Technology (clone 28B10) cat no: 9216),
total p38 MAPK (Cell Signaling Technology cat no: 9212s) b-
tubulin (Millipore (clone AA2) cat no: 05-661) was purchased from
Millipore, goat anti-mouse IRD 700 and goat IRD anti-rabbit 800
were purchased from LI-COR Biotechnology (Lincoln, Nebraska).
IL-6, IL-8 and MCP-1 Duoset ELISAs were purchased from R&D
Technologies (Burlington, ON, Canada). Dimethyl sulphoxide
(DMSO) was purchased from Sigma (St. Loius, MO, USA) and
sodium azide was purchased from sigma (St. Louis, MO, USA).
Cell lysis solution, protease inhibitor cocktail and phosphatase
inhibitor cocktail were purchased from Sigma (St. Loius, MO,
USA). BioRad protein reagent and nitrocellulose membranes were
purchased from Bio-Rad (Mississauga, ON, Canada).
Cell Culture
Human fetal lung fibroblasts (HFL) were purchased from
ATTC (Cat. No CCL-153). Cells were maintained in DMEM
supplemented with 10% (vol/vol) FBS, 100 mg/ml penicillin,
100 mg/ml streptomycin, and kept in a humidified atmosphere
with 5% CO2. All experiments were performed between passages
5–11. Cells were routinely passaged every 4–5 d. For all
experiments, cells were grown to confluency and serum-starved
in DMEM with 0.1% FBS for 24 h before treatment.
Detection of IL-6, IL-8, MCP-1
IL-6, IL-8 and MCP-1 levels were determined using human IL-
6, IL-8 or MCP-1 ELISAs, according to according to manufac-
turer’s protocols. Briefly, cells were seeded in 12-well culture dishes
(1610
6 per well), grown to 90% confluency and serum-starved in
DMEM (0.01% FBS) over-night. Cells were then incubated with
GrK (10–300 nM), in the absence of any delivery/cell permea-
bilizing agent (ie. perforin, streptolysin O), or Thrombin (2.5 U/
ml), at the concentrations and time points indicated for each
experiment in DMEM containing 1% FBS. Supernatants were
collected for analysis by ELISA and the remaining cells were
trypsinized and counted using a hemocytometer. For inhibitor
studies, cells were pre-treated with the ERK inhibitor (U0126;
10 mM) or the p38 MAPK inhibitor (SB202190; 10 mM) or
neutralizing antibodies for 45 min prior to stimulation with GrK
(200 nM) or thrombin (2.5 U). Cells treated with vehicle alone,
heat-inactivated GrK (100 nM, heat-inactivated at 85uC for
5 min) or mouse IgG (5 mg/ml) isotype served as baseline controls.
Western blot analysis of signal transduction pathways in
HFLs upon GrK stimulation
HFL were seeded in 6-well culture dishes at 2610
6 cells/well,
grown to desired confluency, serum-starved over night and then
treated with 10 mM U0126 or 10 mM SB202910 for 45 min prior
to treatment with 200 nM of GrK or 2.5 U/ml of Thrombin.
After 10 min, 30 min, and 2 h, supernatants were collected for IL-
6, IL-8 and MCP-1 determination and remaining cells harvested
for Western blot analysis of the levels of the downstream products
for phospho-p44/42 (ERK1/2) and phospho-p38 MAPK.
Briefly, cells were rinsed with ice-cold Dulbecco’s phosphate-
buffered saline (dPBS) and lysed in 100 ml of cell lysis buffer
containing proteinase inhibitor cocktail and phosphatase-inhibitor
cocktail followed by scraping with a cell scraper. Cell debris was
removed by centrifugation (12,0006g for 15 min) and protein was
quantified by the Bradford method (BioRad) using bovine serum
albumin as standard. Samples containing equal amounts of total
cell protein were separated by 10% SDS-PAGE, and transferred
onto a nitrocellulose membrane using the Bio-Rad wet transfer
system at 100 v for 1 h. The membranes were blocked with 2.5%
skim milk in TBST (50 mM Tris, pH 7.6, 0.15 mM NaCl, 0.1%
Tween 20) for 1 h at room temperature. Membranes were then
incubated with antibodies against phospho-p44/42 MAPK
(1:2000), total p44/42 MAPK (1:1000), phospho-p38 MAPK
(1:2000), p38 MAPK (1:1000) over night at 4uC with gentle
shaking. After several washes in TBST, membranes were
incubated with goat anti-mouse IRD 700 and goat IRD anti-
rabbit 800 for 1 h at room temperature. Flourescent signal was
imaged using the Li-COR Odyssey Infrared imaging system (Li-
COR biosciences). Densitometry was used to quantify all bands.
Membranes were then re-probed with mAb b-tubulin (1:5000) for
1 h at room temperature and incubated with goat anti-mouse IRD
800 for 45 min. The relative levels of phospho-p44/42 MAPK or
phospho-p38MAPK are expressed as the ratio to b- tubulin.
PAR-1 desensitization
For PAR-1 receptor desensitization studies, cells were pre-treated
with 2.5 U/ml of thrombin for 10 min. Media was removed and
cells were washed three times with PBS. For IL-6, IL-8 and MCP-1
measurements, fresh media containing GrK (200 nM) or thrombin
(2.5 U/ml) was then added cells for a 24 h incubation period and
supernatants were collected and screened as described above. In
addition to measuring potential changes in cytokine and chemokine
production, thrombin-induced PAR-1 activation will induce
ERK1/2 phosphorylation. Therefore, we screened for changes in
p44/42 (ERK1/2) activation following receptor de-sensitization in
cells were pre-treated with thrombin. Here cells were pre-treated
with thrombin (2.5 U/ml) for 10 min, media was removed and cells
were washed three times with PBS. Cells were then treated with
either GrK (200 nM) or thrombin (2.5 U/ml) for 10 min. Cell
lysates were then collected as described above and screened for
phospho-p44/42 activation as described.
Cell viability and proliferation
As extracellular GrA and GrB have been shown to induce cell
detachment, we examined the impact of extracellular GrK on cell
Granzyme K Activates PAR-1
PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e21484viability and proliferation in HFLs. Cell viability was measured
using the WST-1 assay (Roche, Ltd. Missasauga, ON, Canada)
according to manufacturer’s instructions. Here, 96-well culture
dishes were seeded with 1610
4 cells and incubated with media
alone or GrK (100 nM, 200 nM) for 24 h. Cells were then
incubated with 1:10 dilution of WST-1 reagent for 3 h and
absorbance was read at 450 nM. Cell proliferation was assessed
using cell counts. Cells were seeded in 12-well culture dishes and
incubated with varying concentrations of GrK for 48 h, with or
without ATAP-2 (5 mg/ml). Cells were then trypsinized, centri-
fuged for 5 min 1006g, re-suspended in 1 ml PBS, diluted 1:1 in
0.4% Trypan Blue and counted using a hemocytometer. Cells
treated with ATAP-2 were incubated for 30 min prior to
treatment with GrK.
Statistical analysis
All data are expressed as mean +/2 SEM for three separate
experiments. Statistical analysis was performed using One-Way
ANOVA followed by Dunnets post hoc analysis for multiple group
comparisons. Differences were considered significant at p,0.05.
Results
Extracellular GrK is not cytotoxic
As extracellular GrA and GrB may induce cell death through
the cleavage of extracellular matrix proteins and the subsequent
induction of anoikis, we examined the impact of extracellular GrK
Figure 1. Extracellular GrK is not cytotoxic. HFLs were serum
starved and incubated with growth media in the presence or absence
of GrK (100 nM, 200 nM) for 24 h and cell viability was assessed using
the WST-1 assay. All data are expressed as mean absorbance 6 SEM
from three independent triplicate experiments.
doi:10.1371/journal.pone.0021484.g001
Figure 2. GrK stimulates IL-6, IL-8 and MCP-1 protein production in lung fibroblasts. (A–C) HFLs were exposed to concentrations of GrK
ranging from 10–300 nM at for 24 h. Cell culture supernatants were then collected and analyzed for IL-6, IL-8 and MCP-1 production by ELISA. Cell
counts were used to normalize cytokine concentrations by controlling for variability in cell numbers. Control wells include cells treated with media
alone or cells treated with heat in-activated GrK (100 nM). All data are expressed as mean protein production (pg/10
6 cells) 6 SEM from three
independent triplicate experiments. * p,0.05 when compared to media alone; ** p,0.01 when compared to media alone.
doi:10.1371/journal.pone.0021484.g002
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viability using the WST-1 assay. As demonstrated in Figure 1,
HFLs treated with 100 and 200 nM of GrK exhibited similar cell
viability to HFLs incubated in media alone (Figure 1).
GrK induces IL-6, IL-8 and MCP-1 production in HFLs
HFLs stimulated with GrK at concentrations ranging from 10–
300 nM (in the absence of perforin or any other delivery agent)
exhibited a dose-dependent increase in IL-6 and IL-8 protein
production in cell culture supernatants at 24 h (Figures 2 A and B).
Incubation with GrK also induced the secretion of MCP-1 though
this release did not appear to be dose-dependent (Figure 2 C).
Enzymatic activity was required to stimulate cytokine and
chemokine production as heat-inactivated GrK (100 nM) did
not induce IL-6, IL-8 or MCP-1 production. Time course
experiments using GrK (200 nM) demonstrated that maximal
release of IL-6, IL-8 and MCP-1 was detected in supernatants at
24 h (data not shown).
Induction of IL-6, IL-8 and MCP-1 in HFLs occurs through
activation of PAR-1
Previous studies have established that HFL express PARs-1-4
[30,31,32]. Given its trypsin-like activity, we examined whether
extracellular GrK was inducing the release of pro-inflammatory
molecules through the cleavage and subsequent activation of
PARs. To address this, we used antibodies to specifically block
PAR-1 and PAR-2 cleavage sites, using a PAR-1 neutralizing
antibody as described previously [33,34,35]. As shown in Figure 3
A–C, incubation with the PAR-1 neutralizing antibody (ATAP-2)
prior to GrK treatment markedly diminished IL-6, IL-8 and
MCP-1 production, whereas incubation with the PAR-2 (Sam11L)
neutralizing antibody had no significant impact on these events. In
the current study, we did not specifically neutralize PAR-3 or
PAR-4 because we observed no cytokine production following
treatment with the potent PAR-4 agonist peptide GYPGQV (data
not shown). While PAR-3 and PAR-4 can be proteolytically
activated by thrombin, evidence suggests that PAR-3 acts as a
cofactor for PAR-4 at low concentrations of thrombin and is a
non-signaling receptor [36]. Furthermore, we observed near
complete ablation of cytokine production using the PAR-1
neutralizing antibody suggesting from a functional standpoint that
most of the biological activity observed following GrK treatment is
the result of PAR-1 activation, but does not completely rule out a
potential role for PAR-3 or PAR-4.
PAR-1 receptor desensitization reduces GrK-induced IL-6,
IL-8 and MCP-1 production
To further verify the specificity of GrK-mediated PAR-1
activation, we used the high affinity ligand for PAR-1, thrombin
(2.5 U/ml) to desensitize PAR-1 prior to exposure to GrK. As
Figure 3. PAR-1 neutralization reduces GrK-induced IL-6, IL-8 and MCP-1 production. Cells were incubated with the PAR-1 neutralizing
antibody (ATAP-2; 5 mg/ml) PAR-2 neutralizing antibody (Sam11L; 25 mg/ml) or mouse isotype IgG control antibody for 30 min prior to incubation
with GrK (200 nM) for 24 h. Supernatants from cell cultures were collected and analyzed for IL-6, IL-8 and MCP-1 production by ELISA. Cell counts
were used to normalized to cell numbers. Data are expressed as % of media control (DMEM+0.0001% NaN3) 6 SEM from three separate experiments
run in triplicate. + p,0.05 when compared to media control; ** p,0.05 when compared to GrK (200 nM) treatment.
doi:10.1371/journal.pone.0021484.g003
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by thrombin prior to incubation with GrK decreased IL-6, IL-8
and MCP-1 production. This was further confirmed by examina-
tion of ERK1/2 phosphorylation where pre-treatment (PT) with
thrombin decreased the level of phosphorylation elicited by
subsequent application of GrK (Figure 4 D).
GrK induces ERK1/2 and p38 MAPK phosphorylation in HFL
It has previously been reported that activation of PAR-1 leads to
the activation of ERK1/2 and p38 MAPK in several cell types,
including fibroblasts [37,38,39]. Thus, we next performed
experiments to determine if GrK activation of PAR-1 induced
ERK1/2 or p38MAPK phosphorylation in HFL. Figure 4 A–D
demonstrates that incubation with GrK (200 nM) induced
phosphorylation of both ERK1/2 and p38MAPK. Phosphoryla-
tion of ERK1/2 was maximal 10 min after stimulation with GrK
and gradually declined to control levels by 2 h incubation (Figure 5
A and B). GrK also induced p38 MAPK phosphorylation with a
similar kinetic profile (Figure 5 C and D).
MAPK activation in PAR-mediated IL-6, IL-8 and MCP-1
release
Using specific pharmacological inhibitors, we assessed the
relative roles of ERK1/2 and p38 MAPK activation on the
synthesis and release of GrK- and thrombin-induced IL-6, IL-8
and MCP-1 in HFL. As shown in Figure 5, pre-treatment of cells
with the MEK1/2 inhibitor U0126 inhibited GrK-induced IL-6
and IL-8 release, and thrombin-induced IL-6, IL-8 and MCP-1
release back to control levels. While a reduction was noted in
GrK-induced MCP-1 levels, levels were not significantly different
from controls (Figure 6 C). In contrast, inhibition of p38 MAPK
with SB202910 (10 mM) had no significant impact on GrK-
induced IL-6, IL-8 or MCP-1 production but did significantly
reduce thrombin-induced IL-6, IL-8 and MCP-1 levels, suggesting
that although GrK can activate p38 MAPKs in HFL, p38 may not
be involved in mediating PAR-1 induced IL-6, IL-8 or MCP-1
production.
GrK stimulates HFL proliferation
Because fibroblasts are a major component of connective tissues
and fibroblasts proliferation is an important process in wound
healing, we examined the functional consequences of GrK-
induced signaling on fibroblast viability and proliferation. As can
be seen in Figure 7, GrK stimulated proliferation in a
concentration dependent manner (A). No significant difference
was detected between controls and GrK-treated cells prior to 48 h
(data not shown). GrK (200 nM)-induced proliferation was
inhibited by ATAP-2 (5 mg/ml) (black bars) suggesting that
Figure 4. Desensitization of PAR-1 with Thrombin (2.5 U/ml) reduces GrK-induced IL-6, IL-8 and MCP-1 production in lung
fibroblasts. (A–C) HFL were treated with thrombin (2.5 U/ml) for 10 min, monolayers were then rinsed three times with fresh media and incubated
with GrK (200 nM) for 24 h. Supernatants were collected and IL-6, IL-8 and MCP-1 levels were analyzed by ELISA. Supernatants were normalized using
cell counts. Data are expressed as % change over media control 6 SEM from three separate experiments run in triplicate. (D) GrK (200 nM) and
thrombin (2.5 U/ml) induced ERK1/2 phosphorylation following 10 min incubation. Pre-treatment (PT) of HFL with thrombin (2.5 U/ml) for 10 min
prior to treatment with GrK (200 nM) for an additional 10 min decreased ERK1/2 phosphorylation when compared to monolayers incubated with GrK
(200 nM) alone. ERK1/2 phosphorylation was assessed by Western blotting of cell lysates using anti-phospho-ERK1/2 and anti-total-ERK1/2
antibodies. Protein loading was verified and normalized using b-tubulin. Data represent the mean 6 SEM of at least three independent experiments.
+ p,0.05 when compared to media control (1% DMSO in DMEM); ** p,0.05 compared to GrK (200 nM) treated cells.
doi:10.1371/journal.pone.0021484.g004
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ated mechanism (B).
Discussion
In this study we demonstrate that GrK can induce pro-
inflammatory cytokine release from human lung fibroblasts
through the activation of PAR-1 and supports previous studies
that have suggested that GrK is not involved in immune-mediated
cytotoxity but rather in the promotion of inflammation
[3,7,40,41]. Previous work by Joeckel et al [7] demonstrated that
GrK induces IL-1b production and secretion from mouse
peritoneal macrophages. The IL-1b processing observed in this
study was dependent on both the concentration of GrK and its
delivery into cells by streptolysin O (SLO). Interestingly, the
authors noted that high concentrations of GrK (600–1000 nM)
resulted in IL-1b production in the absence of SLO. Whether GrK
was exerting this effect via an extracellular or intracellular
mechanism was not established. Our study not only demonstrates
that GrK can promote inflammation through IL-6, IL-8 and
MCP-1 production but also provides evidence that GrK can act
extracellularly to exert this function in the absence of a cell
delivery agent. Given the tryptase-like activity of GrK, and the
role that PARs play in inflammation, it is not unreasonable to
hypothesize that in conditions of elevated, free GrK it could cleave
and activate PAR-1 and promote inflammation.
PAR-1 is involved in a variety of biological events and is the
primary receptor responsible for mediating many of the pro-
inflammatory and pro-fibrotic effects of thrombin [38,39,42].
PAR-1 activation triggers the production of several inflammatory
mediators, including IL-6, IL-8 and MCP-1, and induces cell
proliferation through the coupling of receptor activation to one or
more intracellular signaling pathways [26,27]. In the present work,
neutralizing antibodies and receptor desensitization experiments
suggest that GrK induced IL-6, IL-8 and MCP-1 production is
dependent on PAR-1 activation through a pathway involving
ERK1/2 and p38 MAPK. Furthermore, as is seen with thrombin,
GrK-induced IL-6, IL-8 and MCP-1 production is also dependent
on ERK1/2 and p38MAPK activation [38,39]. While we focused
on ERK1/2 and p38 MAPK signaling in this study, GCPRs can
also initiate other signaling cascades pathways (reviewed in
[26,27,29]). Recently, Deng et al (2008) demonstrated that
MCP-1 release in murine lung fibroblasts was regulated by
multiple pathways including phospholipase C, calcium-dependent
PKC, and Rho kinase signaling pathways [37]. GrK-induced
PAR-1 activation is likely associated with multiple signaling
pathways and further biochemical analysis is required to delineate
which signaling pathways are involved.
Figure 5. Western blot analysis of effect of GrK on ERK1/2 and p38 MAPK phosphorylation. Cells were incubated with GrK (200 nM) for
10 min, 30 min, or 2 h. Cell lysates were collected and screened for (A) ERK1/2 phosphorylation using anti-phospho-ERK1/2 and anti-total-ERK1/2
antibodies and (C) p38 MAPK phosphorylation using anti-phospho-p38MAPK and total p38MAPK antibodies. Cells incubated with ERK1/2 inhibitor
(U0126; 10 mM) or p38MAPK inhibitor (SB202190; 10 mM) prior to treatment with GrK (200 nM) for 10 min are included to demonstrate the activity of
each inhibitor. Densitometry analysis of immunoblots was carried out using Li-COR Odyssey Infrared imaging system (Li-COR biosciences). (B) Relative
levels of ERK1/2 phosphorylation (ERK1 white bars; ERK2 black bars) are expressed as a ratio of phospho-ERK1/2 to total ERK1/2. (D) Relative levels of
p38 MAPK phosphorylation are expressed as a ratio of phospho-p38 MAPK to total p38 MAPK. Protein loading was normalized using b-tubulin. The
values shown are mean +/2 SEM from three separate experiments. * p,0.05 compared to media alone.
doi:10.1371/journal.pone.0021484.g005
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PLoS ONE | www.plosone.org 6 June 2011 | Volume 6 | Issue 6 | e21484Figure 6. ERK1/2 is required for GrK-induced IL-6 and IL-8 production in lung fibroblasts. The effect of U0126 or SB202910 on IL-6, IL-8
and MCP-1 production following GrK (white bars) or thrombin (black bars) treatment. Cells were treated with 10 mM U0126 or 10 mM SB202910 for
45 min prior to exposure to GrK (200 nM) or thrombin (2.5 U/ml) for 24 h. Supernatants were collected and analyzed for protein production by ELISA.
Data are expressed as percent change over vehicle control (1% DMSO in DMEM) 6 SEM from experiments run in triplicate. * p,0.05 when compared
to GrK or thrombin treatment alone.
doi:10.1371/journal.pone.0021484.g006
Figure 7. GrK induces cell proliferation in HFLs in a dose-dependent manner. (A) Cells were incubated with 100 and 200 nM of GrK for 48 h
then trypsinized and counted using a hemocytometer to determine cell number. (B) PAR-1 neutralization with ATAP-2 (5 mg/ml) abolished GrK
(200 nM)-induced cell proliferation. Data are expressed as mean fold change 6 SEM from three independent experiments run in triplicate. * p,0.05
compared to media control.
doi:10.1371/journal.pone.0021484.g007
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extracellular GrK in disease, this is the first study to demonstrate
a physiological role for extracellular GrK in cytokine production.
The observation that GrK can initiate cytokine release and induce
cell proliferation in lung fibroblasts is significant given recent
observations that extracellular GrK is detected in the BAL of
patients with viral pneumonia and allergic asthma [10,11]. IL-6,
IL-8 and MCP-1 are important mediators in the regulation of the
acute-phase response to injury and infection by influencing
immune cell recruitment, as well as the differentiation and
activation of T cells and macrophages [43,44,45]. In the current
study, elevated levels of MCP-1 were detected in supernatants
following treatment with low concentrations of GrK. MCP-1 is
expressed by numerous cell types, including monocytes/macro-
phages, fibroblasts, and epithelial cells, and is a potent chemoat-
tractant for mononuclear cells. In addition to its ability to promote
inflammation, MCP-1 is involved in the recruitment of fibrocytes,
and may exert profibrotic effects by inducing the expression of
transforming growth factor-b and by down-regulating the
production of the major anti-fibrotic prostaglandin E2
[46,47,48]. Interestingly, elevated levels of MCP-1 are correlated
with poor outcomes in patients with interstitial lung disease,
suggesting that GrK may not only influence inflammation, but
may also be involved in tissue repair and airway remodeling
[46,49,50,51,52]. However, whether or not GrK plays a direct role
in the pathogenesis of such diseases will require the use of GrK-
knockout animals that are unavailable at present.
While proteases can positively impact inflammation, chronically
elevated levels of proteases, particularly in the absence of the
appropriate anti-protease, can be detrimental.
In cases of sepsis, elevated levels of free, active GrK and
decreased levels of IAIP correlate with the severity of sepsis.
Elevated levels of extracellular GrK, particularly in the absence of
IAIP, may contribute to the enhanced expression IL-6, IL-8 and
MCP-1 in such conditions. Given that sepsis and pneumonia are
common causes of acute lung injury leading to inflammation and
fibrosis [17], future studies are necessary to determine whether a
causal role of GrK in such diseases exists.
In summary, in the present study we demonstrate that
extracellular GrK is capable of inducing cytokine production
from human lung fibroblasts through the activation of PAR-1.
Future studies are required to fully understand the extracellular
roles of GrK on structural cells within the lung, we well as other
tissues, with the potential that GrK could be targeted therapeu-
tically as a means of reducing PAR-1 mediated inflammation.
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